In early 2000, Leukosite merged with Millenium Pharmaceuticals - itself having been SBIR involved in its early years - 5 Phase I and 1 Phase II. The merger with Leukosite in 1999 brought Millennium its first drug close-to-market, Campath (alemtuzumab) Injection, and additional investigational drugs in clinical trials. LeukoSite developed drugs to block disease promoting actions of white blood cells, with potential applications within the areas of cancer, autoimmune and viral diseases. The firm's small molecule and monoclonal antibody therapeutics for inflammatory, autoimmune, and viral diseases, as well as for cancer applications included products included CAMPATH⢠for the treatment of chronic lymphocytic leukemia, LDP-02 for the treatment of inflammatory bowel disease, LDP-01 for the prevention of post-ischemic reperfusion injury, and LDP-977 for the treatment of bronchial asthma. The company also had nine partner-funded research and discovery programs based on the selective blockade of specific chemokine, chemokine receptor, or integrin controlled leukocyte pathways or functions
